Questions
CJC-1295 Ipamorelin: the questions people actually ask.
Direct answers from the published research — side effects, regulatory status, comparisons, and the limits of what the evidence can say.
What are the bad side effects of CJC-1295 and Ipamorelin?
The most consistent class-level concern is metabolic: a review of growth-hormone secretagogues found increased blood glucose from reduced insulin sensitivity to be the chief safety issue [6]. Growth-hormone-axis stimulation is also tied to fluid retention, puffiness, and carpal-tunnel-type symptoms. Notably, ipamorelin is the first selective secretagogue — it did not raise ACTH or cortisol above releasing-hormone-stimulated levels even at very high doses [2].
What are the downsides to CJC-1295 / Ipamorelin?
The central downside is the evidence gap: the fixed combination has never been tested in a controlled human trial, so its real-world risk profile is unmeasured. Mechanistically, the secretagogue class carries a glucose and insulin-sensitivity signal, fluid retention, and unresolved long-term oncologic questions because growth hormone raises IGF-1, a mitogen [6][1]. Research-grade purity from unregulated suppliers is also unverified.
Is Ipamorelin FDA approved?
No. Neither ipamorelin nor CJC-1295 holds FDA approval as a drug for any indication; both are sold only as research chemicals [6]. A growth-hormone-secretagogue review frames the class as generally well tolerated in short studies but stresses that long-term data on cancer incidence and mortality are still needed [6]. Both peptides are also prohibited at all times in sport under WADA Section S2.
Does CJC-1295 / Ipamorelin cause weight gain?
It can push in both directions. The ghrelin arm (ipamorelin) raised body fat, leptin, and food intake in growth-hormone-intact mice — a growth-hormone-independent adipogenic effect [8] — and the appetite increase users report could add weight. Growth-hormone elevation can also cause transient water retention. The secretagogue class is generally well tolerated, but increased blood glucose from reduced insulin sensitivity is its chief metabolic concern [6].
What is CJC-1295 / Ipamorelin good for?
In research terms, it is a tool for raising endogenous growth hormone and IGF-1. A single dose of CJC-1295 with DAC raised mean plasma growth hormone two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days in healthy adults [1]. Downstream body-composition and recovery effects are extrapolated from single-component and read-across data, not demonstrated for the blend itself.
How long do CJC-1295 and Ipamorelin take to work?
On the hormone level, fast. A single subcutaneous dose of CJC-1295 with DAC raised growth hormone for six days or more and IGF-1 for nine to eleven days, with IGF-1 staying above baseline up to 28 days after multiple doses [1]. Ipamorelin's growth-hormone pulse peaks near 40 minutes post-dose [2]. Any subjective effects people report (sleep, recovery) are described as building over one to several weeks.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not provide a human dose, and no validated human dose for the combination exists — there is no peer-reviewed human pharmacology study of the pre-mixed blend [1]. The research record reports amounts only by species and route, for example CJC-1295 with DAC studied at 30 to 90 µg/kg subcutaneously in healthy adults [1]. None of that is an instruction.
Does CJC-1295 raise testosterone?
CJC-1295 acts on the growth-hormone axis, not directly on testosterone; its documented human effect is multi-day elevation of growth hormone and IGF-1 [1]. There is a cross-species hint from the ghrelin arm: in tilapia, ipamorelin dose-dependently raised luteinizing hormone and 11-ketotestosterone and stimulated germ-cell development [15] — a fish model, not human evidence, and not a basis for any human claim.
Does Ipamorelin reduce belly fat?
Not demonstrated for ipamorelin, and the data is mixed. The closest controlled evidence is for the GHRH analogue tesamorelin: a 2026 meta-analysis of five randomized trials found visceral adipose tissue reduced by a mean of −27.71 cm² and hepatic fat by −4.28% [7]. But ipamorelin itself raised body fat via leptin and appetite in growth-hormone-intact mice [8], so its own effect is not a clean fat-loss signal.
Which is better, Sermorelin or Ipamorelin?
They are different tools, not ranked ones. Sermorelin is a short-acting GHRH analogue working through the releasing-hormone pathway; ipamorelin is a selective ghrelin-receptor agonist working through a separate pathway [2]. The combination rationale is that pairing the two pathways releases more growth hormone than either alone [3][4]. No controlled trial ranks them head-to-head, so "better" depends entirely on the goal and remains unproven.
Can you take both Sermorelin and Ipamorelin together?
Combining a releasing-hormone analogue with a growth-hormone-releasing peptide is exactly the mechanistic strategy behind these stacks. In normal men, submaximal GHRP doses combined with GHRH stimulated growth-hormone release synergistically, the two acting through independent mechanisms [3]. That said, this is research-context mechanism, not a protocol — no controlled human trial validates any specific sermorelin-plus-ipamorelin regimen.
Is Tesamorelin better than Ipamorelin?
On evidence, tesamorelin is far better characterized: a 2026 meta-analysis of five randomized controlled trials showed reduced visceral and hepatic fat, increased lean mass and IGF-1, and no serious adverse events [7]. Ipamorelin has no comparable human outcome trials. But they work through different receptors — tesamorelin on the releasing-hormone pathway, ipamorelin on the ghrelin pathway — so "better" depends on the mechanism you want.
Is Ipamorelin stronger than Sermorelin?
They are not directly comparable on "strength" because they hit different receptors. Ipamorelin is a selective ghrelin-receptor secretagogue that matched GHRP-6's growth-hormone efficacy in swine without raising stress hormones [2]; sermorelin works through the releasing-hormone receptor. The point of the stack is that the two pathways together produce a supra-additive pulse [3][4] — synergy, not a simple potency contest.
Which is safer, Sermorelin or Ipamorelin?
Both share the growth-hormone-axis safety profile — glucose and insulin-sensitivity effects, fluid retention — described for the secretagogue class [6]. Ipamorelin's distinguishing safety feature is selectivity: it did not raise ACTH or cortisol above releasing-hormone-stimulated levels even at doses over 200 times the half-maximal growth-hormone dose [2]. Neither has long-term human safety data, and neither is FDA-approved.
What is CJC-1295 / Ipamorelin?
It is a research combination of two peptides: CJC-1295, a long-acting growth-hormone-releasing-hormone analogue, and ipamorelin, a selective ghrelin-receptor agonist (a growth-hormone-releasing peptide). Used together, they are a growth-hormone-secretagogue stack meant to raise the body's own growth hormone through two pathways at once [2][3]. Neither is FDA-approved, and the fixed combination has never been tested in a controlled trial.
How much CJC-1295 / Ipamorelin should I take?
No validated human amount exists, and this site does not provide dosing. The literature records research amounts by species and route only — for instance, CJC-1295 with DAC studied at 30 to 90 µg/kg subcutaneously in healthy adults [1] — and there is no peer-reviewed human pharmacology study of the pre-mixed combination to draw a combination figure from [1].
Is CJC-1295 / Ipamorelin safe?
The honest answer is that safety is not established for the blend, because the fixed combination has never been trialed. The secretagogue class is generally well tolerated in short studies, with increased blood glucose from reduced insulin sensitivity as the chief concern and long-term cancer and mortality data still needed [6]. Ipamorelin's selectivity — no rise in ACTH or cortisol — is a favorable feature [2], but it is not the same as a long-term safety record.
Does CJC-1295 / Ipamorelin work?
Each half demonstrably raises growth hormone: CJC-1295 with DAC raised growth hormone and IGF-1 for days in healthy adults [1], and ipamorelin is a proven selective secretagogue [2]. Whether the combination produces the downstream body-composition or recovery results people seek is not demonstrated — there is no controlled human trial of the blend, only single-component evidence plus synergy theory [3][4].
How to reconstitute CJC-1295 / Ipamorelin (5mg)?
As a laboratory-handling matter, lyophilised (freeze-dried) peptide is reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), then kept refrigerated at 2 to 8 °C. Reconstituted aqueous peptide degrades over weeks via asparagine deamidation, and agitation and repeated freeze-thaw should be avoided. This is handling context only — not a preparation instruction for human use, which is not a use described on this site.
Where to inject CJC-1295 / Ipamorelin?
The routes studied in the research literature are subcutaneous and intravenous, with continuous subcutaneous infusion (osmotic minipump) and intranasal delivery used in rodent models [1][2]. This site describes routes as they appear in studies, by species; it does not provide self-administration or injection-site instructions, because human self-administration is outside any studied research protocol.
Does Ipamorelin make you hungry / increase appetite?
Yes, that is consistent with its mechanism. Ipamorelin acts on the ghrelin receptor — the hunger receptor — and in growth-hormone-intact mice it raised food intake and serum leptin alongside increased body fat [8]. The secretagogue class is otherwise generally well tolerated, with the main metabolic flag being increased blood glucose from reduced insulin sensitivity [6]. Community reports of post-injection hunger fit this pathway.
Can I take CJC-1295 / Ipamorelin in the morning?
This site does not provide timing instructions. As context, CJC-1295 with DAC produces a multi-day growth-hormone and IGF-1 elevation rather than a single timed pulse [1], whereas ipamorelin produces a short pulse peaking near 40 minutes [2]. Timing choices in research-use communities are not validated by any controlled trial of the combination, so no time-of-day recommendation can be supported from the literature.